← Back to Search

Procedure

Nerve Block for Total Knee Replacement (CACB Trial)

N/A
Recruiting
Led By Naveed Siddiqui, MD
Research Sponsored by Samuel Lunenfeld Research Institute, Mount Sinai Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up at baseline, 24, 48, 72 hours, seven, 30 and 90 days postoperatively
Awards & highlights

Summary

This trial will assess if using a continuous nerve block during knee replacement surgery can reduce opioid use and improve patients' recovery and quality of life.

Who is the study for?
This trial is for adults over 21 years old who are having a knee replacement in a fast track program and have no drug or alcohol dependency. They must be generally healthy (ASA I-III), not dependent on opioids, without allergies to the study drugs, coagulopathy, low platelets, or issues that prevent catheter placement at the surgery site.
What is being tested?
The study tests if continuous adductor canal block (CACB) with ropivacaine provides better pain control and recovery compared to a sham procedure (ShACB) using saline after knee replacement surgery. It measures opioid use, quality of recovery scores, pain levels, side effects from opioids, functional status post-surgery, complications related to the nerve block catheter and hospital readmissions.
What are the potential side effects?
Potential side effects may include typical reactions to local anesthetics like ropivacaine such as nausea, vomiting, dizziness or numbness near the injection site. Complications could also arise from catheter placement like infection or bleeding.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~at baseline, 24, 48, 72 hours, seven, 30 and 90 days postoperatively
This trial's timeline: 3 weeks for screening, Varies for treatment, and at baseline, 24, 48, 72 hours, seven, 30 and 90 days postoperatively for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
opioid consumption
Secondary study objectives
Intensity of postoperative pain
Opioid related side effects
Quality of Recovery

Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: CACBActive Control1 Intervention
continuous adductor canal block
Group II: Control groupPlacebo Group1 Intervention
sham continuous adductor canal block - ShACB

Find a Location

Who is running the clinical trial?

Samuel Lunenfeld Research Institute, Mount Sinai HospitalLead Sponsor
128 Previous Clinical Trials
11,383 Total Patients Enrolled
Naveed Siddiqui, MDPrincipal InvestigatorAssociate Professor
7 Previous Clinical Trials
715 Total Patients Enrolled

Media Library

Continuous Adductor Canal Block (Procedure) Clinical Trial Eligibility Overview. Trial Name: NCT05962970 — N/A
Total Knee Replacement Research Study Groups: CACB, Control group
Total Knee Replacement Clinical Trial 2023: Continuous Adductor Canal Block Highlights & Side Effects. Trial Name: NCT05962970 — N/A
Continuous Adductor Canal Block (Procedure) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05962970 — N/A
~21 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top